Novel gene promoters could improve gene therapies for neurological diseases
Novel promoters based on those in the herpes viruses, enabled delivery of larger genes and increased the period they were active in the nervous system.
List view / Grid view
Novel promoters based on those in the herpes viruses, enabled delivery of larger genes and increased the period they were active in the nervous system.
Researchers have made the genome of the Nicotiana benthamiana plant, a commonly used bio-factory organism, public to aid in COVID-19 vaccine production.
The developers of the lung epithelium model plan to investigate whether SARS-CoV-2 can infect and replicate in the model to assess whether it could be used in the fight against COVID-19.
The TAp63 tumour suppressor protein, two micro RNAs (miRNAs) and the AURKA gene can all suppress cutaneous squamous cell carcinoma (cuSCC) development, find researchers.
Wnt proteins have been extremely difficult to purify in an active state due to their hydrophobic nature arising from post translational lipid modifications.
Researchers have identified which SARS-CoV-2 proteins physically associate with proteins in human cells, revealing potential drug targets to treat the COVID-19 coronavirus.
The team used data from SARS-CoV to identify possible viral epitopes that vaccines could include to stimulate an immune response.
Researchers have identified that copper ions and their protein transporters, such as Atox1, are key to cancer cell movement and could be targeted by therapies.
Researchers have created a new technical resource atlas which maps the 15 distinct cell types involved in muscle repair for disease and therapy research.
A novel antibody has been shown to stimulate microglia to degrade amyloid plaques in a murine model of Alzheimer’s disease.
Scientists have showed that a three inhibitors (3i) cocktail could reprogramme fibroblasts to a naïve embryonic stem cell-like state and remove disease-associated epigenetic changes.
An enzyme that adds a cell-signalling code to proteins has been identified by researchers, who say their discovery could aid in the development of cancer therapies.
Scientists suggest competence-blocking, ‘anti-evolution’ drugs could be administered alongside antibiotics to prolong the period before bacterial resistance emerges.
Research indicates both S. aureus and S. epidermidis exacerbate skin inflammation, so could be targeted to help treat Netherton syndrome.
A computational programme has been created by researchers to aid in the design of proteins for therapeutics, to predict interactions.